872509-56-3 Usage
General Description
2,6-Dichloro-3,5-dimethoxyaniline, also known as dichloroaniline, is a chemical compound with the molecular formula C8H9Cl2NO2. It is an organic compound belonging to the aniline family and is used in the production of dyes and pigments. The compound is a pale yellow to brownish solid and is primarily used as an intermediate in the synthesis of pharmaceuticals and agricultural chemicals. 2,6-Dichloro-3,5-dimethoxyaniline is considered to be moderately toxic and can cause irritation to the skin, eyes, and respiratory system upon exposure. It is important to handle this chemical with caution and proper safety measures in place.
Check Digit Verification of cas no
The CAS Registry Mumber 872509-56-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,5,0 and 9 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 872509-56:
(8*8)+(7*7)+(6*2)+(5*5)+(4*0)+(3*9)+(2*5)+(1*6)=193
193 % 10 = 3
So 872509-56-3 is a valid CAS Registry Number.
872509-56-3Relevant articles and documents
Heterocyclic compounds as FGFR4 inhibitors
-
Paragraph 0127; 0146-0148, (2021/02/10)
The present invention provides heterocyclic compounds as selective inhibitors of fibroblast growth factor receptor 4 (FGFR4), pharmaceutical compositions containing the compounds, methods of preparingthe compounds, and methods of treating cell proliferative diseases, such as cancer, using the compounds of the invention.
Preparation method of kinase inhibitor intermediate
-
, (2021/02/10)
The invention relates to a synthetic method of a kinase inhibitor intermediate, namely 2, 6-dichloro-3, 5-methoxyaniline (I), belongs to the field of organic synthesis, and has the advantages of safeand stable route, convenience in operation, easiness in
FGFR4 INHIBITORS
-
Page/Page column 36, (2016/10/31)
Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.
